Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) ...

C HICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in ...

As China prepares to beef up its weight loss drug market, the Danish firm that makes Ozempic may soon have its dominance ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a ...

A new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal cancer, begging the question ...

Turbocharging the GLP-1 agonist used to treat diabetes and obesity may transform treatment for patients with fatty liver ...

Cost is a major reason for GLP-1 Agonist Discontinuation. (HealthDay News) — Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

New research argues that the oral alternative to injected semaglutide could also help improve the symptoms of diabetes and ...

“Taste perception can vary significantly from person to person, limiting the generalizability of our results,” she said.

Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...

Studies from multiple UChicago experts show that while GLP-1RA drugs are extremely effective for weight loss and Type 2 diabetes treatment, there's no one-size-fits-all solution and physicians and ...